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Abstract
Background: Bevacizumab (BEV) plus triplet chemotherapy can increase efficacy of first-line treatment of
metastatic colorectal cancer (MCRC), particularly integrated with secondary liver surgery in liver-limited (L-L)
patients. The prognostic value of the KRAS genotype in L-L and other or multiple metastatic (O/MM) MCRC
patients treated with the FIr-B/FOx regimen was retrospectively evaluated.
Methods: Tumoral and metastatic samples were screened for KRAS codon 12 and 13 and BRAF mutations by
SNaPshot and/or direct sequencing. Fit MCRC patients <75 years were consecutively treated with FIr-B/FOx
regimen: weekly 12-h timed flat-infusion/5-fluorouracil (TFI 5-FU) 900 mg/m2, days 1, 2, 8, 9, 15, 16, 22 and 23;
irinotecan (CPT-11) 160 mg/m2 plus BEV 5 mg/kg, days 1, 15; oxaliplatin (OXP) 80 mg/m2, days 8, 22; every 4
weeks. MCRC patients were classified as L-L and O/MM. Activity and efficacy were evaluated and compared using
log-rank test.
Results: In all, 59 patients were evaluated: 31 KRAS wild-type (53%), 28 KRAS mutant (47%). At 21.5 months median
follow-up, objective response rate (ORR), progression-free survival (PFS) and overall survival (OS) were, respectively:
KRAS wild-type 90%, 14 months, 38 months; KRAS mutant 67%, 11 months, 20 months. PFS and OS were not
significantly different. PFS and OS were significantly different in L-L compared to O/MM evaluable patients. In KRAS
wild-type patients, clinical outcome of 12 L-L compared to 18 O/MM was significantly different: PFS 21 versus 12
months and OS 47 versus 28 months, respectively. In KRAS mutant patients, the clinical outcome of 13 L-L
compared to 14 O/MM was not significantly different: PFS 11 months equivalently and OS 39 versus 19 months,
respectively.
Conclusions: The KRAS genotype wild-type and mutant does not significantly affect different clinical outcomes for
MCRC patients treated with the first-line FIr-B/FOx intensive regimen. KRAS wild-type patients with L-L disease may
achieve a significantly prolonged clinical outcome due to integration with secondary liver surgery, with respect to
KRAS mutant patients.
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Background
Triplet regimens consisting of chemotherapeutic drugs, or
doublets plus bevacizumab (BEV) (anti-vascular endothe-
lial growth factor monoclonal antibody) or cetuximab
(anti-epithelial growth factor receptor (EGFR) monoclonal
antibody) in EGFR-overexpressing and KRAS wild-type
metastatic colorectal cancer (MCRC), reported overlap-
ping activity and efficacy in phase III trials, ranging
between objective response rate (ORR) 39% to 68%, pro-
gression-free survival (PFS) 7.2 to 10.6 months, overall
survival (OS) 19.9 to 26.1 months [1]. In ‘fit’ MCRC
patients, these first-line options, integrated with secondary
resection of liver metastases, significantly increased survi-
val over doublet regimens [1,2]. More intensive medical
treatment consisting of triplet chemotherapy plus targeted
agents can further increase activity, thus raising resection
rate of liver metastases and clinical outcome [1-5]. Phase
II studies, by Masi et al. [3], and by our group [4], pro-
posed BEV addition to triplet chemotherapy, according to
FOLFOXIRI/BEV or FIr-B/FOx schedules, reaching ORR
77% and 82%, median PFS 13.1 and 12 months, median
OS 30.9 and 28 months, as first-line treatment of MCRC
patients. Liver metastasectomies were performed in 32%
and 26% overall and 40% and 54% liver-only patients,
respectively. Thus, MCRC patients with liver-limited (L-L)
disease, integrating FIr-B/FOx intensive regimen and sec-
ondary liver surgery significantly improved clinical out-
come compared to MCRC patients with multiple
metastatic disease, up to median PFS 17 months and med-
ian OS 44 months [6].
Gain-of-function mutations of RAS, BRAF, PIK3CA
genes, or loss of tumor suppressor function of PTEN,
resulting in continuous activation of the RAS-mitogen-
activated protein kinase (MAPK) or phosphoinositide 3-
kinase (PI3K) pathways, characterize most colorectal can-
cers (CRC) [7-9]. KRAS mutations represent an early event
in colorectal tumorigenesis [10,11] and occur in 35% to
45% of CRC, mostly represented by codon 12 c.35 G>A
(32.5%) [12,13], c.35 G>T (22.5%) [11,12], and codon 13,
prevalently c.38 G>A, transversions [14]. They impair
intrinsic GTPase activity of KRAS, and lead to constitutive,
growth factor receptor-independent activation of down-
stream signaling [15]. BRAF mutations, prevalently c.1799
T>A (V600E) mutation, characterize 4.7% to 8.7% of CRC
[16-20].
Clinical outcome (PFS, OS) according to wild-type and
mutant genotype assesses the prognostic relevance of a
specific biomarker, potentially including the predictive
role of effectiveness of treatment strategies. In randomized
studies, the predictive relevance of wild-type or mutant
genotype can also be specifically assessed by comparing
experimental and control arms. The reported median OS
values of KRAS wild-type and mutant MCRC patients
treated with irinotecan, 5-fluorouracil and leucovorin (IFL)
plus BEV were 27.7 and 19.9 months, respectively [18,21].
The prognostic relevance of KRAS or BRAF wild-type
compared to KRAS or BRAF mutant genotype was not sig-
nificantly different, even though the hazard ratio (HR) was
0.64 and 0.38, respectively. A significantly better prognosis
was reported only when KRAS/BRAF wild-type patients
were compared with patients harboring mutations in the
KRAS or BRAF genes (HR 0.51) [18]. KRAS wild-type gen-
otype significantly predicts a favorable clinical outcome of
anti-EGFR or anti-vascular endothelial growth factor
(VEGF) drugs added to doublet chemotherapy [18,21-23].
In the KRAS mutant genotype, BEV addition to IFL signifi-
cantly prolonged PFS up to 9.3 months, without increasing
OS and activity, compared to IFL [18,21].
Here, we report a retrospective exploratory analysis eval-
uating the prognostic value of the KRAS genotype in
MCRC patients enrolled in a previously reported phase II
study [4] and in an expanded clinical program proposing
FIr-B/FOx intensive regimen as first-line treatment, also
verifying recently reported significantly greater effective-




MCRC patients were enrolled in a previously reported
phase II study [4] and in the expanded clinical program
proposing FIr-B/FOx association as first-line treatment.
Patients were eligible if they had a histologically confirmed
diagnosis of measurable MCRC; were age 18 to 75 years;
had World Health Organization (WHO) performance sta-
tus ≤2; had adequate hematological, renal and hepatic
functions; and had a life expectancy more than 3 months.
The study was approved by the Local Ethical Committee
(Comitato Etico, Azienda Sanitaria Locale n.4 L’Aquila,
Regione Abruzzo, Italia) and conducted in accordance
with the Declaration of Helsinki. All patients provided
written, informed consent.
Schedule
The FIr-B/FOx regimen was developed from previously
reported doublet and triplet chemotherapy schedules
[24,25], consisting of weekly timed flat-infusion/5-fluor-
ouracil (TFI 5-FU), without leucovorin, associated to
weekly alternating irinotecan (CPT-11)/BEV or L-oxalipla-
tin (OXP) [4]: TFI 5-FU (Fluorouracil Teva; Teva Italia,
Milan, Italy), 900 mg/m2/day, over 12 h (from 10:00 pm to
10:00 am), days 1, 2, 8, 9, 15, 16, 22 and 23; CPT-11
(Campto; Pfizer, Latina, Italy), 160 mg/m2, days 1, 15; BEV
(Avastin; Roche, Welwyn Garden City, United Kingdom),
5 mg/kg, days 1, 15; l-OXP (Eloxatin; Sanofi-Aventis,
Milan, Italy), 80 mg/m2, days 8, 22; cycles every 4 weeks.
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Mutational analysis
KRAS and BRAF genetic analyses were performed on par-
affin-embedded tissue blocks from the primary tumor
and/or metastatic sites. Genotype status was assessed for
KRAS codon 12 and 13 mutations and BRAF c.1799 T>A
(V600E) mutation by SNaPshot® multiplex screening for
KRAS mutations and KRAS/BRAF mutations in 36 and
32 samples, respectively [26,27]; direct sequencing was
performed for detection of KRAS mutations in 23 sam-
ples and to confirm detected mutations. After treatment
with xylene thyocyanate and selection of tumoral cell
clusters, DNA was isolated using the RecoverAll™ Total
Nucleic Acid Isolation Kit for FFPE Tissues (Applied Bio-
systems, Courtaboeuf, France) according to manufac-
turer’s instructions. When considering the contamination
of tumoral samples by non-malignant cells, a KRAS
mutation in the tumor was defined as appearance of a
mutant peak with a height of at least one-third compared
to the wild-type.
SNaPshot and Direct Sequencing assays
SNaPshot multiplex assay was performed as elsewhere
reported [26,27]. Briefly, KRAS exon 2 and BRAF exon 15
were simultaneously amplified by polymerase chain reac-
tion (PCR) using specific primers and purified using
NucleoSpin® Extract II kit (Macherey-Nagel EURL,
Hoerdt, France). PCR-amplified DNA was analyzed using
the ABI PRISM SNaPshot Multiplex kit (Applied Biosys-
tems, Foster City, CA, USA) and five primers including
an additional tail at their 5’ end allowing their simulta-
neous detection. Sense primers allowing the extension at
nucleotides KRAS c.34G, c.35G, c.37G, c.38G and BRAF
c.1799T were used and a multiplex SNaPshot reaction
was performed as reported [26]. KRAS exon 2 sequencing
was performed from PCR-amplified tumor DNA using
the Big Dye V3.1 Terminator Kit (Applied Biosystems,
Foster City, CA, USA). Labeled products were separated
using an ABI Prism 3130xl Genetic Analyzer (Applied
Biosystems, Foster City, CA, USA). Data were analyzed
using the GeneMapper Analysis Software version 4.0
(Applied Biosystems, Foster City, CA, USA).
Study design
A retrospective analysis was planned to evaluate prognos-
tic relevance of KRAS genotype on clinical outcome of
MCRC patients treated with FIr-B/FOx as first-line treat-
ment. Moreover, patients were classified according to
involved metastatic sites, L-L and O/MM [6], to evaluate
the relevance of metastatic extension in KRAS wild-type
and mutant MCRC patients. Patients with L-L metastases
were evaluated at baseline and every three cycles of treat-
ment by a multidisciplinary team, consisting of a medical
oncologist, liver surgeon and radiologist, to dynamically
evaluate resectability defined according to resectability
categories previously reported [6]. Resection rate was eval-
uated in the intent-to-treat population enrolled. Liver
metastasectomies were defined as R0, if radical surgery,
R1, if radioablation was added. Surgery was recommended
>4 weeks after BEV discontinuation. Clinical evaluation of
response was made by computed tomography (CT) scan;
positron emission tomography (PET) was added based on
investigators’ assessment.
Clinical criteria of activity and efficacy were ORR, PFS
and OS. ORR was evaluated according to Response Eva-
luation Criteria In Solid Tumors (RECIST) criteria [28];
pathologic complete response was defined as absence of
residual cancer cells in surgically resected specimens. The
overall activity of integrated medical treatment and sec-
ondary liver surgery, consisting of the sum of clinical com-
plete responses (cCR) and liver metastasectomies was also
evaluated, as previously reported [6]. PFS and OS were
evaluated using the Kaplan-Meier method [29]. PFS and
PFS from surgery were defined, respectively, as the length
of time from the beginning of treatment or the date of
liver metastasectomy and disease progression or death
(resulting from any cause) or to the last contact; OS as the
length of time between the beginning of treatment and
death or to last contact. The Log-rank test was used to
compare PFS and OS in KRAS wild-type versus mutant, L-
L versus O/MM, and KRAS wild-type L-L versus O/MM,
and KRAS mutant L-L versus O/MM MCRC patients [30].
Results
Patient demographics
A total of 59 tumoral samples of 64 enrolled MCRC
patients (92%) were available: 46 primary tumors and 13
metastases (7 liver, 4 peritoneal carcinomatosis, 1 local
recurrence and 1 lung). Demographic and baseline fea-
tures of patients were representative of the overall phase
II study population (Table 1). The number of MCRC
patients with KRAS wild-type and mutant genotypes was
31 (53%) and 28 (47%), respectively (Table 1); the male/
female ratio was 21/10 and 16/12; synchronous meta-
static disease, 21 (68%) and 21 (75%) patients. Patients’
distribution according to extension of metastatic disease,
L-L and O/MM, was, respectively: overall, 25 (42%) and
34 (58%); KRAS wild-type, 12 (39%) and 19 (61%); KRAS
mutant, 13 (46%) and 15 (54%). Table 2 shows KRAS
mutations detected in 28 patients: codon 12, 24 patients
(85.7%), specifically c.35 G>A 15 patients (53.5%), c.35
G>T 7 patients (25%), c.34 G>A and c.35 G>C, 1 patient
each; codon 13, 4 patients (14.2%), c.38 G>A 3 patients
(10.7%) and c.37_39 dupl, 1 patient. A total of 32
tumoral samples (54%) were also analyzed for BRAF and
no BRAF mutation was detected; 18 out of 31 KRAS
wild-type MCRC patients were KRAS and BRAF wild-
type; 14 out of 28 KRAS mutant MCRC patients were
BRAF wild-type. EGFR protein expression was positive
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in 35 patients (59%) and negative in 24 patients (41%):
among KRAS wild-type patients, positive in 23 patients
(74%) and negative in 8 patients (26%); among KRAS
mutant patients, positive in 13 patients (40%) and nega-
tive in 15 patients (60%).
Activity and efficacy
Overall activity and efficacy data (Table 3) were similar to
that reported in the phase II study: ORR was 79% (95%
CI 68 to 90); liver metastasectomies were performed
in 18 patients (31%), 17 out of 25 L-L patients (68%).
Table 1 Patients’ features
KRAS wild-type, no. (%) KRAS mutant, no. (%) Total no. (%)
No. of patients 31 (53) 28 (47) 59
Male/female 21/10 16/12 37/22
Age, years:
Median 64 65 63
Range 42 to 73 48 to 73 42 to 73
≥65 13 (42) 13 (46) 26 (44)
WHO performance status:
0 28 (90) 26 (93) 54 (92)
1 to 2 3 (10) 2 (7) 5 (8)
Metastatic disease:
Metachronous 10 (32) 7 (25) 17 (29)
Synchronous 21 (68) 21 (75) 42 (71)
Primary tumor:
Colon 14 (45) 20 (71) 34 (58)
Rectum 17 (55) 8 (29) 25 (42)
Sites of metastases:
Liver 19 (61) 20 (71) 39 (66)
Lung 7 (23) 5 (18) 12 (20)
Lymph nodes 10 (32) 8 (29) 18 (30)
Local 6 (19) 3 (11) 9 (15)
Other 2 (6) 6 (21) 8 (14)
No. of involved sites:
1 17 (55) 17 (61) 34 (58)
≥2 14 (45) 11 (39) 25 (42)
Single metastatic sites:
Liver limited 12 (39) 13 (46) 25 (42)
Other than liver 7 (22) 4 (15) 11 (19)
Lung 2 (6) 2 (7) 4 (7)
Lymph nodes 2 (6) 1 (4) 3 (5)
Local 3 (10) 1 (4) 4 (7)
Multiple metastatic sites 12 (39) 11 (39) 23 (39)
Liver metastases:
Single 8 (26) 3 (11) 11 (19)
Multiple 11 (35) 11 (39) 22 (37)
Previous adjuvant chemotherapy: 6 (19) 2 (7) 8 (14)
FA/5-FU bolus 3 (10) - 3 (5)
Capecitabine - - -
FOLFOX4 2 (6) 2 (7) 4 (7)
XelOx 1 (3) - 1 (2)
Previous radiotherapy: 4 (13) 1 (4) 5 (8)
Radiotherapy alone - - -
Radiotherapy + chemotherapy (5-FU continuous infusion) 2 (6) - 2 (3)
Radiotherapy + chemotherapy (XELOX) 2 (6) 1 (4) 3 (5)
WHO = World Health Organization.
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After a median follow-up of 21.5 months, median PFS
was 12 months (1+ to 69+ months), median OS was 28
months (1+ to 69+ months). Among 30 evaluable KRAS
wild-type patients, ORR was 90% (95% CI 79 to 100). We
observed 27 objective responses: 23 partial responses
(77%) and 4 complete responses (CRs) (13%); 2 stable
diseases (7%); 1 progressive disease (3%). Disease control
rate was 97% (95% CI 90 to 100). Liver metastasectomies
were performed in 11 patients (35%), 10 out of 12 L-L
patients (83%). Median PFS was 14 months (1+ to 69+
months), 25 events occurred. Median OS was 38 months
(1+ to 69+ months), 17 events occurred. Among the 18
KRAS/BRAF wild-type patients, ORR was 83% (95% CI
69 to 97), median PFS was 13 months (4 to 44 months),
median OS was 31 months (8 to 66+ months). Among 27
evaluable KRAS mutant patients, ORR was 67% (95% CI
49 to 85). We observed 18 objective responses: 17 partial
responses (63%) and 1 CR (4%); 4 progressive diseases
(16%). Disease control rate was 85% (95% CI 71 to 99).
Liver metastasectomies were performed in 7 patients
(25%) out of 13 L-L patients (54%). Median PFS was 11
months (1+ to 60+ months), 20 events occurred. Median
OS was 20 months (1+ to 60+ months), 17 events
occurred. Overall, R0 liver resections made up 13 out of
18 liver metastasectomies (72%). Pathologic CRs were
obtained in 2 patients (11%), both KRAS mutant patients,
harboring codon 12 mutations, c.35 G>T and c.34 G>A,
with multiple liver-only metastases. In one KRAS wild-
type patient with single liver associated with lung metas-
tases, double metastatic resections were performed. KRAS
wild-type compared with mutant patients did not show
significantly different PFS nor OS, even if OS seems to be
favorable in KRAS wild-type patients (Figure 1).
We verified previously reported findings of significantly
different outcome (PFS and OS) with FIr-B/FOx accord-
ing to extension of metastatic disease [6] in KRAS wild-
type and mutant patients (Table 4). Among 25 evaluable
L-L patients, ORR was 84% (95% CI 69 to 99); overall
activity was 80% due to 17 performed liver metastasec-
tomies (68%) and 3 cCRs (12%) in patients who did not
undergo liver surgery showing PFS of 69+, 60+, and 40+
months, respectively; median PFS was 17 months (3 to
69+ months); median OS was 47 months (8 to 69+
months). Among the 17 L-L patients who underwent
liver metastasectomies, the median PFS was 18 months
Table 2 KRAS mutations
Exon Codon Hot spot site Amino acid No. of patients %
2 12 24 40.6
c.34 G>A p.Gly12Ser 1 1.6
c.35 G>A p.Gly12Asp 15 25.4
c.35 G>T p.Gly12Val 7 11.8
c.35 G>C p.Gly12Ala 1 1.6
13 4 6.7
c.37_39 dupl p.Gly13 dupl 1 1.6
c.37 - - -
c.38 G>A p.Gly13Asp 3 5
Table 3 Activity, efficacy and effectiveness of FIr-B/FOx regimen according to KRAS genotype
Intent to treat analysis
KRAS wild-type KRAS mutant All
No % No % No %
Enrolled patients 31 100 28 100 59 100
Evaluable patients 30 97 27 96 57 97
Objective response 27 90 (95% CI 79 to 100) 18 67 (95% CI 49 to 85) 45 79 (95% CI 68 to 100)
Partial response 23 77 17 63 40 70
Complete response 4 13 1 4 4 7
Stable disease 2 7 5 18.5 7 12
Progressive disease 1 3 4 15 5 9
Median PFS, months 14 11 12
Range 1+-69+ 1+-60+ 1+-69+
Progression events 25 81 20 71 45 76
Median OS, months 38 20 28
Range 1+-69+ 1+-60+ 1+-69+
Deaths 17 55 17 61 34 58
Liver metastasectomies 11 7 18
No/overall patients 11/31 35 7/28 25 18/59 31
No/patients with liver metastases 11/19 58 7/20 35 18/39 46
No/patients with L-L metastases 10/12 83 7/13 54 17/25 68
Pathologic complete responses - - 2 28.5 2 11
L-L = liver limited; OS = overall survival; PFS = progression-free survival.
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(8 to 35+ months); median OS was 47 months (10+ to 56
+ months). Among 32 evaluable O/MM patients, the
ORR was 80% (95% CI 64 to 96), overall activity was 9%
due to 1 performed liver plus lung metastasectomies (3%)
and 2 cCRs (6%) in patients who did not undergo liver
surgery and showing PFS of 22, and 4+ months, respec-
tively; median PFS was 12 months (1+ to 44 months);
median OS was 21 months (1+ to 66+ months). Clinical
outcome (PFS and OS) in L-L compared to O/MM
patients was significantly different (Figure 2A).
Among the 30 evaluable KRAS wild-type patients,
ORR in 12 L-L and 18 O/MM patients were 100% and
80%, respectively. Overall activity was 100% (ten liver
metastasectomies and two cCRs) in L-L and 17% (one
liver plus lung metastasectomy and two cCRs) in
O/MM patients, respectively. Significantly different
clinical outcome was confirmed in L-L compared to
O/MM, respectively (Figure 2B): median PFS 21 months
(8 to 69+ months) versus 12 months (4 to 44 months)
(p 0.044); median OS 47 months (18+ to 69+ months)
versus 28 months (1+ to 66+ months) (p 0.017). Among
the 27 evaluable KRAS mutant patients, ORR in 13 L-L
and 14 O/MM patients were 67% and 80%, respectively.
Overall activity in L-L patients was 62% (seven liver
           
       
               (1)                                                     (2)  
Figure 1 Kaplan-Meier survival estimate. Overall population, KRAS wild-type versus KRAS mutant. 1, Progression-free survival; 2, overall survival.
Table 4 Activity, efficacy and effectiveness of FIr-B/FOx regimen according to KRAS genotype and extension of
metastatic disease
All KRAS wild-type KRAS mutant
L-L O/MM L-L O/MM L-L O/MM
Evaluable patients 25 32 12 18 13 14
Objective response (%; 95% CI) 21 (84; 69 to 99) 24 (80; 64 to 96) 12 (100) 15 (80; 59 to 100) 9 (67; 40 to 94) 9 (80; 54 to 100)
Partial response 18 22 10 13 8 9
Complete response 3 (12) 2 (6) 2 (17) 2 (11) 1 (8) -
Stable disease 2 3 - 2 2 3
Progressive disease 2 3 - 1 2 2
Liver metastasectomies, N (%) 17 (68) 1 (3) 10 (83) 1 (6) 7 (54) -
Pathologic complete responses 2 (12) - - - 2 -
Overall activitya, N (%) 20 (80) 3 (9) 12 (100) 3 (17) 8 (62) -
Median PFS, months 17 12 21 12 11 11
Range 3-69+ 1+44 8-69+ 4-44 3-60+ 1+37
Progression events 20 27 10 15 10 12
P value 0.034 0.044 0.354
Median OS, months 47 21 47 28 39 19
Range 8-69+ 1+66+ 18+69+ 1+66+ 8-60+ 1+59+
Deaths 12 23 4 13 8 10
P value 0.013 0.017 0.225
aClinical complete response plus metastasectomies.
L-L = liver limited; O/MM = other/multiple metastatic site; OS = overall survival; PFS = progression-free survival.
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metastasectomies and one cCR) while no liver metasta-
sectomy nor cCR was obtained in O/MM patients. The
comparison of PFS and OS in KRAS mutant L-L and O/
MM patients was not significantly different: median PFS
11 months (3 to 60+ months) versus 11 months (1+ to
37 months), respectively; median OS 39 months (8 to
60+ months) versus 19 months (1+ to 59+ months),
respectively (Figure 2C).
            
           
             (A1)                                                    (A2)  
         
           
             (B1)                                                    (B2)  
                     
            
           
             (C1)                                                    (C2)  
Figure 2 Overall survival, Kaplan-Meier survival estimate. (A) Liver only versus multiple metastatic sites; (B) liver-only versus multiple
metastatic sites, KRAS wild-type; (C) liver-only versus multiple metastatic sites, KRAS mutant. 1, Progression-free survival; 2, overall survival.
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Discussion
In KRAS wild-type patients, BEV addition to doublet che-
motherapy significantly increased ORR, PFS and OS up to
60% to 61%, 10.5 to 13.5 months and 21.8 to 27.7 months,
respectively [18,21,31,32]. Randomized studies of anti-
EGFR added to doublets, in EGFR-overexpressing patients,
reported ORR 50% to 61%, PFS 7.7 to 10.6 months, OS
22.4 to 24.9 months [22,23,31-33]. First-line cetuximab
plus FOLFOX4, significantly improved ORR and PFS in
KRAS/BRAF wild-type population, similarly to KRAS wild-
type patients [34]. In KRAS mutant patients, BEV addition
to doublet chemotherapy (IFL) significantly increased
median PFS up to 9.3 months, while ORR was equivalent
to doublet arm (43.2% and 41.2%, respectively), and med-
ian OS increased up to 19.9 months, even if not signifi-
cantly [21,35].
In KRAS wild-type and mutant MCRC patients, BEV
addition to triplet chemotherapy, according to FIr-B/FOx
schedule, reported high activity and efficacy: ORR 90%
and 67%, median PFS 14 and 11 months, median OS 38
and 20 months, respectively. A similar clinical outcome
was also obtained in KRAS/BRAF wild-type patients.
Equivalent efficacy was reported with FOLFOXIRI/BEV
regimen: ORR 82% and 71%, median PFS 13.6 and 12.6
months, respectively [3]. In unresectable colorectal liver
metastases, ORR 79%, median PFS 14 months, median OS
37 months were reported with chrono-IFLO/cetuximab
[5].
Median PFS and OS values of MCRC patients treated
with FIr-B/FOx were different in KRAS wild-type and
mutant patients, even if not significantly, while they were
equivalent in the FOLFOXIRI plus BEV study [3]. BEV
addition to doublet IFL chemotherapy gave median PFS
13.5 and 9.3 months, median OS 27.7 and 19.9 months in
KRAS wild-type and mutant patients, respectively [18,21].
Significantly better prognosis was reported in KRAS/BRAF
wild-type patients compared with patients harboring
mutations in the KRAS or BRAF genes (HR 0.51) [18].
Direct comparison of OS between KRAS wild-type and
mutant MCRC patients treated with BEV-containing che-
motherapy failed to significantly differentiate prognosis, as
in the present study. Thus, intensive regimens adding BEV
to triplet chemotherapy can further increase activity and
efficacy in KRAS wild-type and mutant patients. Rando-
mized studies would be able to properly evaluate this.
The high activity of triplet chemotherapy plus BEV regi-
mens correlated with increased resection rate of liver
metastases and pathologic CR, particularly in L-L MCRC
patients [1,3,4,6]. We recently reported that the clinical
outcome of L-L compared to multiple metastatic disease
was significantly improved up to median PFS 17 months
and median OS 44 months [6] due to the effectiveness of
integrated FIr-B/FOx intensive treatment and secondary
liver surgery. The present analysis confirms the signifi-
cantly favorable prognosis of L-L compared to MM
patients and show that KRAS wild-type L-L patients,
accounting for 20% of fit MCRC patients, could gain 100%
overall activity with an integrated medical and surgical
approach, due to performed liver metastasectomies and
long-lasting cCRs; median PFS 21 months and OS 47
months. A significantly favorable prognosis was demon-
strated in KRAS wild-type L-L compared to O/MM
patients, even if this represents a retrospective, exploratory
analysis in a small cohort of MCRC patients. Using neoad-
juvant cetuximab with either FOLFOX6 or FOLFIRI for
unresectable colorectal liver metastases, metastasectomies
were performed in 38% and 30% patients, respectively
[36]. Chrono-IFLO/cetuximab reported a 60% R0 resec-
tion rate in unresectable colorectal liver metastases, with
ORR 79%, median PFS 14 months and median OS 37
months [5]. Further prospective studies will properly
address whether intensive medical treatments, such as FIr-
B/FOx, and secondary liver surgery could represent the
standard multidisciplinary strategy for KRAS wild-type L-L
MCRC patients. In KRAS mutant patients, prevalently har-
boring c.35 G>A transversion (53.5%), integrated medical
and surgical treatment failed to significantly increase PFS
and OS in L-L compared to O/MM patients: median PFS
was equivalent (11 months), in spite of 54% performed
liver metastasectomies in L-L patients; median OS was 39
and 19 months, respectively. These data should be further
evaluated in a larger cohort of MCRC patients. A proper
multidisciplinary treatment strategy for KRAS mutant
patients, showing different aggressiveness [37], sensitivity
to medical treatment, and worse clinical behavior, is an
unmet need.
Conclusions
KRAS wild-type and mutant genotypes do not significantly
affect the clinical outcomes of MCRC patients treated
with the first-line FIr-B/FOx intensive regimen. KRAS
wild-type patients with L-L disease may achieve signifi-
cantly greater benefit from integration with liver metasta-
sectomies compared to O/MM metastatic extension, with
respect to KRAS mutant patients. The present findings
should be verified in prospective trials of multidisciplinary
strategies comparing clinical outcome according to KRAS
genotype in patients with L-L and O/MM disease.
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